Sodium-glucose co-transporter inhibitors

Australian Prescriber

Volumn 37, Issue 1, 2014, Pages 14-16

  Thynne, Tilenka ^a   Doogue, Matthew ^b  

^a Department of Clinical Pharmacology   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Canagliflozin; Dapagliflozin; Diabetes mellitus type 2; Hypoglycaemic drugs; Kidney

Indexed keywords

ANTIDIABETIC AGENT; CANAGLIFLOZIN; DAPAGLIFLOZIN; HEMOGLOBIN A1C; LOOP DIURETIC AGENT; SODIUM GLUCOSE COTRANSPORTER; SODIUM GLUCOSE COTRANSPORTER INHIBITOR; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; DEHYDRATION; DRUG GLUCURONIDATION; DRUG MECHANISM; GLUCOSE REABSORPTION; GLUCOSE TRANSPORT; GLUCOSURIA; HUMAN; HYPEROSTOSIS; HYPOGLYCEMIA; INSULIN RESISTANCE; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE ABSORPTION; MILD RENAL IMPAIRMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORTHOSTATIC HYPOTENSION; URINARY TRACT INFECTION;

EID: 84893265448     PISSN: 03128008     EISSN: None     Source Type: Journal    
DOI: 10.18773/austprescr.2014.005     Document Type: Article

References (14)

1. Bailey CJ. Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci 2011;32:63-71.
2. Hummel CS, Lu C, Loo DD, Hirayama BA, Voss AA, Wright EM. Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2. Am J Physiol Cell Physiol 2011;300:C14-21.
3. Chen J, Williams S, Ho S, Loraine H, Hagan D, Whaley JM, et al. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther 2010;1:57-92.
4. Santer R, Calado J. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 2010;5:133-41.
5. Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev 2005;21:31-8.
6. Kasichayanula S, Liu X, Griffen SC, Lacreta FP, Boulton DW. Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin. Diabetes Obes Metab 2013;15:280-3.
7. Taylor JR, Dietrich E, Powell JG. New and emerging pharmacologic therapies for type 2 diabetes, dyslipidemia, and obesity. Clin Ther 2013;35:A3-17.
8. US Food and Drug Administration. FDA briefing document: NDA 202293. Dapagliflozin tablets, 5 and 10 mg. Advisory Committee meeting July 19, 2011. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm262994.pdf [cited 2013 Nov 19]
9. US Food and Drug Administration. FDA Briefing Document: NDA 204042. Invokana (canagliflozin) tablets. Advisory Committee meeting January 10, 2013. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM334550. pdf [cited 2013 Nov 19]
10. Rossi S, editor. Australian Medicines Handbook 2013. Adelaide: Australian Medicines Handbook Pty Ltd; 2013.
11. Clar C, Gill JA, Court R, Waugh N. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open 2012;2:e001007.
12. Bolinder J, Ljunggren O, Kullberg J, Johansson L, Wilding J, Langkilde AM, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012;97:1020-31.
13. European Medicines Agency Committee for Medicinal Products for Human Use. Assessment Report: Forxiga. Dapagliflozin. London: EMA; 2012. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_ assessment_report/human/002322/WC500136024.pdf [cited 2013 Nov 14]
14. Davis T. Experimental and clinical pharmacology. Sodium-glucose co-transporter inhibitors-clinical applications. Aust Prescr 2014;37:17-20.